Menopur

Menotropin, the active ingredient in Menopur, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It is employed to treat infertility caused by anovulation and to stimulate controlled ovarian stimulation in assisted reproductive technology cycles, supporting follicular development.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Menopur (menotropin) is used in reproductive hormone therapy to support ovarian follicle development.

Infertility due to anovulation: promotes follicular growth to enable ovulation. Controlled ovarian stimulation for assisted reproductive technology: enhances multiple follicle development for IVF or ICSI cycles. Ovulation induction for intrauterine insemination (IUI): facilitates timed ovulation to improve IUI success rates.

Menopur may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Abdominal discomfort: mild pain or cramping in the lower abdomen. - Injection site reaction: redness, swelling, or bruising at the injection site. - Bloating: sensation of fullness or abdominal distension. - Nausea: mild to moderate feeling of queasiness.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome: severe ovarian enlargement with fluid shift and possible complications. - Thromboembolic events: rare blood clots that may be life‑threatening. - Allergic reaction: rash, urticaria, or anaphylaxis. - Ectopic pregnancy: rare but serious implantation outside the uterus.

Before initiating Menopur therapy, clinicians should consider several precautionary measures to ensure patient safety.

Patient assessment: evaluate ovarian reserve and baseline hormone levels before initiating therapy. Monitoring: perform regular ultrasound and estradiol monitoring to detect excessive response. Contraindications: avoid use in active ovarian cysts, uncontrolled thyroid disease, or hormone‑dependent malignancies. Pregnancy status: do not use in confirmed pregnancy. Risk of OHSS: educate patients about symptoms and seek immediate care if severe. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications, affecting its efficacy or safety.

Major Interactions (Avoid): - GnRH agonists or antagonists: may amplify ovarian response and increase OHSS risk. - Hormonal contraceptives: can interfere with the intended stimulation cycle. - Anticoagulants: increase risk of bleeding at injection sites.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may affect ovarian response and require dose adjustment. - Steroids: can alter hormone metabolism and influence stimulation outcomes. - Insulin or oral hypoglycemics: monitor glucose as hormonal changes may affect metabolic control.